Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (7018)	8/28/1999 7:41:00 PM
From: Vector1	Respond to of 9719

Yes, they are trying to get an abstact out for presentation at the ICCAC conference at the end of Sept. Abstacts accepted late usually show very powerful and important info. V1

To: LLCF who wrote (7018)	8/28/1999 11:25:00 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 9719

I've seen some of the data on the TRMS compound. The mechanism seems to be solid, and the data is quite compelling. There are several papers out, primarily from Peter Kim's lab, that provide structural data verifying the mechanism of viral entry. Of course this does not appear to apply for the chemokine co-receptor mechanisms. Of interest is that the TRMS peptide has sufficient stability to to do the job for a significant period of time. The only question is will it only be of use and be cost effective in protease inhibitor resistant patients.